Open-Label Lesinurad Monotherapy Extension Study in Gout

Inclusion Criteria

• - Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study related activity.
• - Subject completed the double-blind treatment period in Study RDEA594-303 and was actively receiving and tolerating study medication (lesinurad or placebo) at Month 6 visit.
• - Subject is willing to adhere to the visit/protocol schedules.
• - Subject is male or female; female subjects of childbearing potential must agree to use an effective non-hormonal method of birth control during the study and for at least 14 days after the last dose of study medication.